Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CR8020 and CR6261 in Hospitalized Influenza A Patients
NCT01992276Phase 2Withdrawn
- Sponsor
- Crucell
- Start
- Dec 2013
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of CR8020, diridavumab in Influenza A (IAV), sponsored by Crucell. Planned start Dec 2013; status: withdrawn.
02
Drugs
CR8020diridavumab
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT01992276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01992276.